Immune Checkpoint Inhibitors (ICI) have improved cancer prognosis but may induce immune-related adverse events, including ICI-induced diabetes mellitus (ICI-DM), a rare yet severe form of autoimmune diabetes. This paper reviews ICI-DM pathogenesis, clinical features, and management, focusing on the potential of advanced technologies – such as CGM, smart MDI, and hybrid closed-loop systems – to optimize glycemic control and improve outcomes in this emerging patient population.